Optimal dosing of sulfadoxine-pyrimethamine (SP) as intermittent preventive treatment in pregnancy remains to be established, particularly when coadministered with azithromycin (AZI). To further characterize SP pharmacokinetics in pregnancy, plasma concentration-time data from 45 nonpregnant and 45 pregnant women treated with SP-AZI (n ϭ 15 in each group) and SP-chloroquine (n ϭ 30 in each group) were analyzed. Population nonlinear mixed-effect pharmacokinetic models were developed for pyrimethamine (PYR), sulfadoxine (SDOX), and N-acetylsulfadoxine (the SDOX metabolite NASDOX), and potential covariates were included. Pregnancy increased the relative clearance (CL/F) of PYR, SDOX, and NASDOX by 48, 29, and 70%, respectively, as well as the relative volumes of distribution (V/F) of PYR (46 and 99%) and NASDOX (46%). Coadministration of AZI resulted in a greater increase in PYR CL/F (80%) and also increased NASDOX V/F by 76%. Apparent differences between these results and those of published studies of SP disposition may reflect key differences in study design, including the use of an early postpartum follow-up study rather than a nonpregnant comparator group. Simulations based on the final population model demonstrated that, compared to conventional single-dose SP in nonpregnant women, two such doses given 24 h apart should ensure that pregnant women have similar drug exposure, while three daily SP doses may be required if SP is given with AZI. The results of past and ongoing trials using recommended adult SP doses with or without AZI in pregnant women may need to be interpreted in light of these findings and consideration given to using increased doses in future trials.
is a high prevalence of parasites with pfdhps K540E, an epidemiologic marker of the quintuple mutation (4), there is attenuated efficacy of SP IPTp (6) . Although SP IPTp remains a useful and highly cost-effective intervention for reducing the incidence of placental malaria, low birth weight, and/or maternal anemia in areas without such high-grade parasite resistance (6, 7) , alternative preventive strategies need to be considered.
Azithromycin (AZI) is a semisynthetic azalide with a broad spectrum of antibacterial activity and a relatively long terminal elimination half-life (t 1/2 ) (8, 9) . It is used widely in the treatment of respiratory and sexually transmitted bacterial infections (10, 11) and is active against both P. falciparum and P. vivax (12) (13) (14) (15) (16) (17) (18) (19) through inhibition of protein synthesis in the plasmodial apicoplast (20, 21) . Its antimalarial activity is of slow onset and relatively weak, but it is effective as treatment (13, 15, 22) and chemoprophylaxis (18, 23) , especially when used in combination with other antimalarial drugs (14, 16, 24) . Since AZI is safe in pregnancy (25, 26) , the potential of SP combined with AZI (SP-AZI) as IPTp has been investigated in several studies, but the results have been variable (27) (28) (29) (30) (31) . Although AZI has fewer interactions than related macrolide antibiotics (32, 33) , a possible explanation for the inconsistent efficacy of SP-AZI is that AZI has a clinically significant interaction with one or other of the components of SP (32) . There have, however, been no comparative studies of the pharmacokinetics of AZI and SP alone and in combination in either nonpregnant patients or pregnant women.
We have previously performed two separate pharmacokinetic studies involving SP in pregnancy. In the first, we characterized the disposition of SP after chloroquine (CQ) after SP (CQ-SP) (34) and, in the second, we examined the disposition of AZI (but not SP) after SP-AZI (35) . In both studies, women in the pregnant group were matched with nonpregnant women from their communities in the same area of north coastal Papua New Guinea (PNG). The principal aim of the present study was to use pooled SP data from both these studies (published from the study of CQ-SP [34] and unpublished SP plasma concentration data from the second study [35] ) to investigate, for the first time, the pharmacokinetic interaction between SP and AZI. In view of apparent inconsistencies in the pharmacokinetic properties of SP in pregnancy (34, 36 ) (see Discussion), a secondary aim was to reevaluate the disposition of SP in pregnancy in the context of the present findings and recent data relating to SP metabolism during gestation and lactation.
RESULTS
Participant characteristics. Data from a total of 90 women (45 pregnant and 45 nonpregnant) were included in the present analysis. Of these, 30 from each group received SP-CQ, and the remaining 15 received SP-AZI. The baseline characteristics of the women by pregnancy status and treatment allocation are shown in Table 1 . The groups were well matched except that, consistent with physiological changes during gestation (37, 38) , the pregnant women were a mean 2.8 kg heavier (P ϭ 0.02) and had a 2.5 g/liter lower mean hemoglobin concentration (P Ͻ 0.01) and a faster heart rate (P Ͻ 0.01) than the nonpregnant women in each treatment group. Twenty of the pregnant women were parasitemic at baseline compared to only three in the nonpregnant group (P Ͻ 0.01). Women allocated AZI were taller by a mean of 4 cm than those who did not take AZI and they had a more rapid heart rate, and pregnant SP-AZI women were sampled an average of 1 week earlier in gestation than were pregnant CQ-SP women (P Ͻ 0.01 for all comparisons). Pharmacokinetic modeling. (i) Pyrimethamine. There were 1,197 plasma PYR concentrations available for analysis, of which 18 (1.5%) were below the LOQ (BLQ) during the 42-day follow-up period. Of these, 10 (0.8%) were below the limit of detection (LOD) and were excluded from the analysis, while the remaining eight (0.7%) were below the limit of quantification (LOQ) and above the LOD and were included as their measured values. A two-compartment model fitted the data better than a one-compartment model, with a significant decrease in the objective function (OFV; P Ͻ 0.001) and improved conditional weighted residuals (CWRES) plot. The addition of a third compartment did not result in additional improvements in the fit. A mixed-order absorption with simultaneous zero and first-order absorption without lag time provided the best absorption model for the plasma concentration-time data. The structural model parameters were k a,PYR , DUR PYR , V C /F PYR , V P /F PYR , CL/F PYR , and Q/F PYR (see Materials and Methods). Interindividual variability was estimable for all structural parameters with a full covariance block for all parameters with the exception of k a,PYR and DUR PYR .
A number of significant covariate relationships were identified. Pregnancy was associated with a higher V C /F PYR , V P /F PYR , and CL/F PYR , with effect sizes of 46, 99, and 48%, respectively. In addition, the coadministration of AZI was associated with an 80% higher CL/F PYR . During the testing of covariates, the effect of pregnancy on CL/F PYR was not evident in the AZI group since there was no significant difference between the CL/F PYR in nonpregnant and pregnant women who were given AZI. The final model parameter estimates and the bootstrap results for PYR are summarized in Table 2 . Bias was Ͻ4 and Ͻ3% for all fixed and random model parameters, respectively. Figures 1 and 2 show goodness-of-fit plots and the prediction corrected visual predictive checks (pcVPCs) stratified according to pregnancy status and administration of AZI, respectively. The pcVPCs stratified by AZI administration were similar.
The post hoc individual parameters t 1/2 s and AUC 0 -∞ are summarized for each subject group in Table 3 . For all women combined, the median distribution and terminal elimination t 1/2 s were 65 and 294 h, respectively, and the median PYR AUC 0 -∞ was 72,364 g·h/liter. In pregnant versus nonpregnant women, both t 1/2 values were longer in pregnancy (medians of 74 h versus 57 h and 363 versus 238 h, respectively; P Ͻ 0.01 in each case), consistent with the larger central and peripheral volumes of distribution, whereas AZI administration resulted in lower values for both (medians of 55 h versus 67 h and 254 versus 306 h; P ϭ 0.01 and 0.20, respectively). Overall, there was a significant reduction in the AUC 0 -∞ associated with both pregnancy (median, 61,415 g·h/liter versus 88,576 g·h/liter; P Ͻ 0.01) and the administration of AZI (median, 52,416 g·h/liter versus 85,014 g·h/liter; P Ͻ 0.01) due to a higher CL/F PYR . However, in those who received AZI, there was no difference in CL/F PYR (median of 1.46 liters/h versus 1.33 liters/h; P ϭ 0.57) or AUC 0 -∞ (median of 51,426 g·h/liter versus 54,913 g·h/liter; P ϭ 0.57) associated with pregnancy. The median AUC 0 -∞ of PYR in pregnant women who received AZI was less than half that in nonpregnant women who did not (51,426 g·h/liter versus 107,476 g·h/liter).
(ii) Sulfadoxine and N-acetylsulfadoxine. There were 1,181 SDOX and NASDOX paired drug concentrations that were available for analysis. Of these, none of the SDOX and 48 (4.1%) of the NASDOX data were BLQ. Since these did not represent a significant proportion of the data, those between LOQ and LOD (26 values [2.2%]) were kept at their measured values, while those below the LOD (22 values [1.9%]) were excluded from the data set.
Initial modeling of the SDOX plasma concentration-time data alone demonstrated that a two-compartment model was significantly better than a one-compartment model (P Ͻ 0.001) with improved model diagnostics, while the addition of a third compartment did not result in further improvement. Absorption of SDOX was best described by a first-order absorption with a lag time. The structural model parameters at this time were, therefore, k a,SDOX , LAG SDOX , V C /F SDOX , V P /F SDOX , CL/F SDOX , and Q/F SDOX . The NASDOX data were then added, and both SDOX and NASDOX plasma concentrations were modeled simultaneously. The addition of a single compartment for NASDOX was adequate in describing the time course of plasma NASDOX concentrations, with no significant benefit in OFV or diagnostic plots in the addition of a second compartment. The additional structural parameters were V/F* NASDOX and CL/F* NASDOX . The IIV of all terms with the exception of LAG SDOX and V P /F SDOX could be estimated. A full covariance block for V C /F SDOX , CL/F SDOX , V/F* NASDOX , and CL/F* NASDOX was included. Both CL/F SDOX and CL/F* NASDOX were significantly higher in pregnancy, with increases of 29 and 70%, respectively. Pregnancy was also associated with a higher V/F* NASDOX (46%), as was the administration of AZI (76%).
The final model parameter estimates and the bootstrap results for the final combined SDOX and NASDOX model are summarized in Table 4 . Bias was Ͻ5% for all fixed and random parameters. Figures 3 and 4 show goodness-of-fit plots and pcVPCs stratified according to pregnancy. The fraction of BLQ data, which was disproportionate between the two groups, was fitted well by the current model without the need for methods to handle this data. Further pcVPCs stratified by AZI coadministration demonstrated similar results. There appeared to be a bias in NASDOX CWRES plots both at latter time points and at lower population predicted concentrations, which can be attributed to the data points that are BLQ and thus could not be included. These points would be expected to have negative residuals, given their low values, and would therefore balance the bias seen in the plots. The post hoc individual parameters t 1/2 values and AUC 0 -∞ are summarized for each subject group in Table 5 . For all women combined, the median t 1/2␣,SDOX , t 1/2␤,SDOX , and t 1/2,NASDOX were 87, 183, and 4.8 h, respectively, and the median AUC 0 -∞,SDOX and AUC 0 -∞,NASDOX were 26,471 and 1,283 mg·h/liter, respectively. In pregnant versus nonpregnant women, pregnancy was associated with a lower AUC 0 -∞,SDOX (medians of 22,807 mg·h/liter versus 34,026 mg·h/liter; P Ͻ 0.01) and AUC 0 -∞,NASDOX (917 mg·h/liter versus 1,789 mg·h/liter; P Ͻ 0.01). There was no significant effect of AZI administration on the AUC of either SDOX or NASDOX (P ϭ 0.73 and 0.25, respectively). The ratio of AUC 0 -∞,NASDOX to AUC 0 -∞,SDOX was not significantly different between any of the study groups with a median and an interquartile range (IQR) of 4.6% and 3.8 to 5.3%, respectively.
Simulations. The results of the simulations for PYR and SDOX are presented in Tables 6 and 7 and displayed in Fig. 5 and 6, respectively. Since AZI did not alter any pharmacokinetic parameter for SDOX, Fig. 6 provides a comparison of nonpregnancy versus pregnancy simulations with or without AZI administration combined. Compared to nonpregnancy without AZI, simulations of pregnancy with AZI administration revealed an approximate halving of the PYR AUC (52,635 g·h/liter versus 101,297 g·h/liter) and an approximate 25% reduction in SDOX AUC (22,523 g·h/liter versus 29,818 mg·h/liter). Simulations of a double dose (six SP tablets together) and two daily conventional doses assumed no dose-or time-dependent kinetics. Therefore, both resulted in a doubling of the AUC for PYR and SDOX.
With nonpregnancy without AZI as a reference, PYR simulations in pregnancy with or without AZI showed plasma PYR concentrations on day 7 that were 53 and 65%, respectively, of the reference group values, whereas the day 28 concentrations were 35 and 57%, respectively. Simulations of two conventional PYR doses 24 h apart in pregnancy generated day 7 and 28 concentrations that were at least 80% of those in the reference group. This regimen of two conventional daily doses resulted in a similar AUC, but higher day 7 and 28 plasma PYR concentrations and a lower C max , compared to a double dose given once. Day 7 and 28 plasma PYR concentrations were lowest in simulations of nonpregnancy with AZI (96 and 5.4 g/liter or 49 and 22%, respectively, versus the reference group). Two conventional daily doses would result in AUC and day 7 concentrations that were similar to those of the reference group, while three conventional daily doses would be required for comparable day 28 plasma PYR concentrations.
For SDOX, differences between simulated groups were less marked and administration of AZI had no effect. Pregnancy did not alter the C max , but there was a lower AUC. Day 7 and 28 SDOX concentrations were also lower in pregnancy (47 mg/liter versus 60 mg/liter, and 3.9 mg/liter versus 8.4 mg/liter, respectively). A double dose given once and two conventional daily doses resulted in similar increases in plasma SDOX concentrations relative to those in the reference group on day 7 (by 157% and 163%, respectively) and day 28 (by 93 and 91%, respectively). As with PYR, when two daily conventional doses were simulated, the C max was lower than a double dose given once. For NASDOX, pregnancy was associated with a 42% lower AUC and a 28% lower C max . Taking into consideration these simulations, two conventional doses of SP 24 h apart would provide PYR and SDOX AUC, and day 7 and day 28 concentrations that were similar in pregnancy and nonpregnancy whether or not they were administered with AZI.
DISCUSSION
We found that pregnancy significantly increased the relative clearance of PYR, SDOX, and NASDOX, suggesting that a double dose of SP is required in pregnant women to achieve drug exposure equivalent to that in women who are not pregnant. This confirms the same recommendation from our previous publication involving a subset of the present data from Papua New Guinea (PNG) (34) . The novel finding in the present population pharmacokinetic analyses is that the administration of AZI with SP resulted in an even greater increase (an approximate doubling) in relative clearance of PYR than observed in pregnancy. This would theoretically justify three daily conventional doses of SP with AZI in pregnancy so that day 28 plasma PYR and SDOX concentrations (and thus durable malaria prevention) were similar to those in nonpregnant women treated with a single dose of SP alone. Despite a large number of completed (27) (28) (29) (30) and continuing trials examining the efficacy SP-AZI IPTp, this represents the first assessment of possible interactions between its components. Our findings suggest that efficacy may be compromised by the possibility of subtherapeutic plasma SDOX and especially PYR concentrations in pregnant women allocated to conventional SP-AZI dose regimens.
There are inconsistencies between the results of different studies that have examined the disposition of SP in pregnancy. These studies are summarized in Table 8 . In the four African groups included by Nyunt et al. (36) and in the Kenyan study by Green et al. (39) , comparisons were made between pregnancy and the postpartum period. There are two potentially major issues with this study design. First, participant retention can be problematic as there was an average attrition rate of 30% in these studies (36, 39) . Second, U.S. Food and Drug Administration guidance suggests that pharmacokinetic comparisons should be made based on a follow-up study at least 3 months postpartum (40) . This recommendation is due to the fact that renal function may take many months to normalize after delivery (41) (42) (43) in concert with postpartum persistence of pregnancyrelated changes in cardiovascular function (41) (42) (43) (44) (45) . In three of the five African groups, the median postpartum period was Ͻ3 months (see Table 8 ).
The ratios of SDOX AUCs in nonpregnant or postpartum women to those in pregnancy, or ratios for median day 7 plasma concentrations for the women from Mozambique and Sudan from only a single sample was collected (36) , are shown in Table 8 . The two lowest values of these parameters were from the groups from Zambia and Mali in which postpartum studies were performed relatively early (36) . In contrast, the largest values were from studies (including the present study) that incorporated a nonpregnant matched comparator group (46) . This suggests that a significant reduction in SDOX exposure during pregnancy may be missed if comparative postpartum pharmacokinetic data are collected close to delivery.
Interpretation of published PYR data is more complex. In three groups, there was a higher PYR exposure in pregnancy (Mali, Mozambique, and Zambia [36] ), two showed no effect of pregnancy (Sudan and Kenya [36, 39] ), and two showed a lower exposure in pregnancy (PNG and Uganda [34, 46] ; see Table 8 ). Nyunt et al. have suggested three potential mechanisms that might account for these discrepancies (36) . First, it could be that the parasitemic women included in the Kenyan and PNG studies (34, 39) influenced the findings. However, both of these studies assessed the potential impact of malaria status on PYR pharmacokinetics of PYR, either using linear regression analysis of individually obtained pharmacokinetic parameters (39) or a stepwise covariate search within a population pharmacokinetic model (34) , and found no effect. Other studies in infants have also found that malaria status did not influence the disposition of PYR (47) . Although there is some in vitro evidence that PYR clearance is impaired in malaria infected rat livers (48), this has not been confirmed in humans. Second, different PYR assay methods may have contributed to the observed differences, but the same assay was used within each study for samples from both groups of women. Third, coadministration of CQ in the PNG study may have influenced PYR disposition. The combination of SP and CQ has been used extensively, and no significant pharmacokinetic interactions have been observed (49) . Consistent with this finding, there are no obvious plausible mechanisms relating to absorption, metabolism or excretion that could underlie an effect of CQ on the pharmacokinetics of PYR (or SDOX), including in pregnancy.
Since none of these explanations appear likely, we suggest that the effect of lactation may have been unrecognized. In the women participating in the African studies in which a lower exposure to PYR in pregnancy was not seen (36) , all were postpartum and very likely to have been lactating at the time of second pharmacokinetic study given the high rate of breastfeeding (Ն84%) continuing to 1 year postpartum in these countries (2) . There is loss of PYR into breast milk, but the amount is small, representing approximately 2% of the total dose (50-52). Of potentially greater significance is the possibility of increased PYR metabolism during lactation.
Animal studies have shown that lactation results in increased mRNA for hepatic enzymes, including from the CYP superfamily (53, 54) . Although the metabolic fate of PYR in humans is unclear, the drug is metabolized primarily by the liver to polar metabolites, which are then excreted, along with PYR in urine and feces in animal models (55) . A study which examined 13 common human CYPs identified PYR as a substrate for CYP1B1 and 2C19 (56); however, the search was not extensive, and other CYPs are likely to play a role in its metabolism. Although human studies of altered hepatic metabolism with lactation have not been performed, there is also evidence that prolactin can alter drug-metabolizing hepatic enzymes (57) . A further consideration is that the mRNA of many CYP enzymes, including 1B1 and 2C, has been identified in mammary tissues and the fat layer of human milk (58-60), with CYP1B1 having the highest mRNA expression of all CYP enzymes in mammary tissue (59) . Given the proliferation of mammary cells that occurs in pregnancy, the increased presence of these enzymes in breast tissue may also help explain the reduction in systemic PYR exposure during pregnancy. Additional data from studies of the human milk fat layer transcriptome demonstrate that there are changes in the expression of CYPs from colostrum through transitional milk to mature milk with a mixture of unchanged, increased, and decreased expression (58) . Therefore, as seen with other enzymatic functions of mammary tissue, lactation can act as a switch for cytochrome P450 enzymes in the breast (61) . Although there is a gradual decline in maternal mammary tissue after birth, higher activity of certain CYP (such as 1B1 in the case of PYR) would lead to increased clearance of its respective substrates and therefore lower exposure in the breastfeeding state. Although there are plausible explanations for between-study discrepancies in the effect of pregnancy on PYR pharmacokinetics, Nyunt et al. found there were differences between African study sites in a multivariate analysis (36) . There is no published information of the effect of food on the absorption of PYR, but it is a Biopharmaceutics Drug Disposition Classification System class 3 compound with food predicted to reduce AUC (62, 63) . Food intake was not controlled in the published studies, and the effect of fed versus fasted state may have contributed to variability in PYR absorption in pregnancy versus nonpregnancy. Although this food-associated variability in absorption may help explain differences in AUC, it would not account for pregnancyassociated changes in elimination. We found that AZI significantly increased the clearance of PYR with a greater effect size than pregnancy. In addition, the effect of pregnancy on AZI clearance was not observed in those women given AZI, suggesting maximal induction of metabolizing enzymes or effect on cellular transporters that are only partially increased with pregnancy. Although AZI has fewer interactions than other macrolides, interactions with antihistamines, calcineurin inhibitors, sulfonylureas, and ivermectin have been reported (32, 33) . The exact mechanisms of these interactions have not been defined, but they are more likely be mediated through inhibition or induction of drug transporters such as P-glycoprotein and organic anion-transporting polypeptide (64) rather than metabolizing enzyme systems since AZI has limited effects on CYP enzymes (32, 33) .
The most recent World Health Organization (WHO) IPTp recommendation is that SP that should be administered as a single dose at each antenatal care visit from beginning of second trimester, with each dose at least 1 month apart (2) . Although there is evidence that this practice may be contributing to parasite mutations associated with resistance (65), SP remains effective in most areas where malaria is endemic, while optimal dosing is likely to at least slow the progression of resistance gene acquisition by the parasite (2) . A number of IPTp trials of SP-AZI have been performed which have not yet been considered by the WHO. A study in PNG demonstrated that a monthly dose of AZI (four 1-g administrations) combined with SP reduced low birth weight, preterm delivery, maternal parasitemia, active placental malaria, and carriage of gonorrhea while increasing birth weight compared to a single SP-CQ dose (30) . In a Malawian study, the addition of two daily 1-g AZI doses to monthly SP reduced fetal and neonatal growth faltering (28, 29) , with a trend toward a reduction in sexually transmitted diseases (28) , even if there was no additional benefit with regards the prevalence of malaria at delivery (27, 28) . Since AZI monotherapy has been shown to have relatively long-lasting effects on malaria parasitemia (66), the lack of expected increased malaria protection with added AZI in these studies may be explained, in part, by lower PYR exposure in pregnancy when coadministered with AZI, as demonstrated by the present study.
In the light of the present and other published data, we suggest a higher dose of SP could be utilized in IPTp, particularly when given in combination with AZI. Given that there is evidence of declining bioavailability with increasing mg/kg doses of AZI (47), the exposure after a single high dose would be less predictable than if it were divided into two or more lower doses. Although this strategy may impair compliance, AZI should be given on at least 2 days. Based on our simulations, the administration of a second conventional SP dose without AZI at 24 h in pregnant women would result in comparable AUC, and day 7 and 28 concentrations for SDOX and PYR with only a minimal increase in C max compared to nonpregnant women. The potential toxicity of SP with higher dose regimens needs to be considered. Severe SP-associated cutaneous reactions are rare and not clearly related to plasma concentration, daily dose, or cumulative dose. Therefore, while pharmacovigilance programs should continue, an increased dose would be not expected to increase the incidence of these rare idiosyncratic reactions (67) . Hematologic reactions such as megaloblastic anemia and bone marrow suppression are dose related. A report of daily dosing of PYR (25 to 100 mg/day) with sulfa drugs (either sulfadiazine, sulfamethazine, or sulfamerazine) in 87 cases of toxoplasma uveitis demonstrated a dose-related bone marrow suppression that completely reversed with folic acid supplementation or cessation of the drug (28, 68) . Since this occurred after 7 to 10 days of daily dosing, it is not expected that a second conventional dose of SP would result in bone marrow suppression, particularly in the context of conventional prepartum folic acid supplementation. In a study of HIV patients receiving PYR for primary prophylaxis for cerebral toxoplasmosis, where hematologic toxicity was noted only after 6 months of 50 mg PYR given three times weekly, similar protective effects of folic acid supplementation were found (69) .
The present study had limitations. The groups of PNG women who were treated with SP-CQ were studied several years before those who received SP-AZI, and it is possible that temporal changes in variables such as nutritional status may have influenced the results. Nevertheless, the same study site was used, and the methods of recruitment, dosing, blood sampling, and drug assays were the same. Although the groups were well matched, there were statistically significant differences in height and gestational age. However, body weight is related to height and was utilized as a covariate in modeling. The difference in gestational age was small (the median was 1 week shorter in the AZI pregnancy group) and thus unlikely to have contributed to significant differences in drug disposition, especially since gestational age did not perform better than pregnancy as a dichotomous covariate in our modeling, and there were no pharmacokinetic differences between the second and third trimesters in the study of SP utilizing a crossover design (46) . Although the numbers of women participating in the present and most previous studies could be considered small, the clinical recommendations from the present analyses are based on effects of key variables including pregnancy and AZI administration on population pharmacokinetic parameter estimates that were relatively large and which had 95% confidence intervals (95% CIs) well away from no effect.
We suggest that the present analyses and our reinterpretation of published data help with understanding why the results of pharmacokinetic studies of SP in pregnancy appear discordant. In addition, our simulations suggest that conventional regimens should be replaced by higher doses if SP is used as IPTp, especially if combined with AZI. This approach would not only improve protection from malaria during pregnancy but could slow the development of parasite resistance. There is a need for further appropriately designed clinical trials, particularly in African populations for which SP IPTp is currently recommended, to confirm our findings.
MATERIALS AND METHODS
Study site, sample, and approvals. The studies from which the present data were collected were conducted at Alexishafen Health Centre, Madang Province, on the north coast of PNG (34, 35) between February 2006 and March 2008. In the present analyses, those women receiving SP with CQ or AZI were included. Safety, tolerability, and efficacy data have been published (34, 35) . Both studies were approved by the Medical Research Advisory Committee of the PNG Department of Health, and the Human Ethics Research Committee of the University of Western Australia approved the study involving SP-AZI. Written informed consent was obtained from all participants. The pregnant women were recruited at their first antenatal clinic visit, and the age-matched nonpregnant volunteers were recruited from the same rural communities as the pregnant participants. Women were eligible if (i) they had not taken any of the study drugs in the previous 28 days, (ii) they had no history of significant allergy to any study drug, (iii) there was no significant comorbidity or clinical evidence of severe malaria, and (iv) follow-up was possible for the duration of the study.
Clinical procedures. Study procedures were identical for pregnant and nonpregnant women. A detailed assessment was performed prior to drug administration including a side effect questionnaire, point-of-care hemoglobin and blood glucose (HemoCue, Angelholm, Sweden), thick and thin blood films, and (for pregnant participants) estimation of gestational age by fundal height. A 3-ml blood sample was taken for subsequent antimalarial drug assay. All women received a single dose of SP (1,500 mg of SDOX plus 75 mg of PYR; Fansidar, Roche, Basel, Switzerland) at enrollment. In addition, either 2 g AZI (Zithromax, Pfizer, New York, NY) at enrollment and 24 h later (SP-AZI) or CQ (Chloroquin; Astra, Sydney, Australia) 450 mg base daily for 3 days (SP-CQ) was given. The administration of all doses was directly observed.
The scheduling of blood samples taken for drug assay differed between the two dose groups. Following the dose of SP, additional blood samples were taken at 1, 2, 3, 6, 12, 24, 32, 40, 48 , and 72 h and then on days 4 and 5 (SP-AZI group) or at 1, 2, 4, 6, 12, 18, 24, 30, 48 , and 72 h (CQ-SP group). All participants were sampled on days 7, 10, 14, 28, and 42. The exact timing of each blood sample was recorded. All samples were centrifuged promptly with red cells, and separated plasma was stored frozen at Ϫ80°C. After the completion of follow-up, pregnant women were returned to usual antenatal care.
Laboratory methods. Giemsa-stained thick blood smears were examined independently by at least two skilled microscopists who were blinded to pregnancy and treatment status. Each microscopist viewed Ͼ100 fields at ϫ1,000 magnification before a slide was considered negative. Any slide discrepant for positivity/negativity or species determination was referred to a third microscopist for adjudication.
Assay methods. Sulfadoxine, sulfamethazine, and PYR were obtained from Sigma-Aldrich Australia, Castle Hill, Australia, and midazolam hydrochloride was obtained from Pfizer Australia, West Ryde, Australia. N-Acetysulfadoxine (NASDOX) was synthesized according to the method of Whelpton et al. (70) and found to have a melting point of 230°C and Ͼ99.9% purity by high-pressure liquid chromatography (HPLC). Acetonitrile was obtained from Merck, Darmstadt, Germany. All other chemicals were of analytical or HPLC grade. The extraction methods for SDOX, NASDOX, and PYR in plasma were based on previously published methods (34) . Separations were performed on a Lichrospher RP Select B column (5 m, 250 by 4 mm [inner diameter]; Merck Gmbh, Darmstadt, Germany) at 30°C. For SDOX and NASDOX, the mobile phase of 25% (vol/vol) acetonitrile in 0.01% (vol/vol) phosphoric acid and 0.01% (wt/vol) NaCl and was pumped at 1.5 ml/min. For PYR, the mobile phase contained 30% (vol/vol) acetonitrile in 0.01% (vol/vol) phosphoric acid and 0.01% (wt/vol) NaCl and was pumped at 1 ml/min. All analytes were detected by their UV absorbance at 270 nm, and analysis of chromatograms was undertaken using Chemstation software (v9; Agilent Technology, Waldbronn, Germany).
For SDOX, the intraday relative standard deviations (RSDs) were 6.2, 5.3, and 5.1% at 1, 50, and 250 mg/liter, respectively (n ϭ 5), while interday RSDs were 8.7, 7.2, and 5.4% at 1, 50, and 250 mg/liter, respectively (n ϭ 25). For NASDOX, intraday RSDs were 7.7, 4.2, and 4.3% at 0.1, 1, and 10 mg/liter, respectively (n ϭ 5), while interday RSDs were 9, 7.7, and 5.7% at 0.1, 1, and 10 mg/liter, respectively (n ϭ 25). For PYR the intraday RSD's were 5.5, 5.6, and 4.6% at 5, 200, and 1000 g/liter, respectively (n ϭ 5), while interday RSDs were 8, 6.9, and 4.6% at 5, 200, and 1,000 g/liter, respectively (n ϭ 25). The LOQs for SDOX, NASDOX, and PYR were 0.1 mg/liter, 0.02 mg/liter, and 2.5 g/liter, respectively. The LOD for SDOX, NASDOX, and PYR were 0.05 mg/liter, 0.05 mg/liter, and 1 g/liter, respectively, with signal-tonoise ratios of 5.
Pharmacokinetic modeling. Log e plasma concentration-time data sets for PYR and SDOX with NASDOX were analyzed by nonlinear mixed effects modeling using NONMEM (v7.2.0; ICON Development Solutions, Ellicott City, MD) with an Intel Visual FORTRAN 10.0 compiler. A first-order conditional estimation with an interaction estimation method was used. The minimum value of the OFV, CWRES plots, visual diagnostic plots, and condition number Ͻ1,000 were used to choose suitable models during the model-building process. A significance level of P Ͻ 0.01 was set for comparison of nested models. Allometric scaling was used a priori, with volume terms multiplied by (body weight/70) 1.0 and clearance terms by (body weight/70) 0.75 . The residual variability (RV) was estimated as an additive error for the log-transformed data.
Secondary pharmacokinetic parameters, including area under the curve (AUC 0 -∞ ) and elimination t 1/2 s were obtained from post hoc Bayesian predictions in NONMEM using the final model parameters. Base models were parameterized using k a (the first-order absorption rate constant), LAG (lag time), DUR (duration of zero-order absorption), V C /F (central volume of distribution), CL/F (clearance), V P /F, and Q/F [peripheral volumes of distribution(s) and their respective intercompartmental clearance(s)], where F represents the bioavailability of PYR and SDOX. For the parent-metabolite pair of SDOX and NASDOX, complete conversion was assumed for modeling purposes to allow for identifiability; therefore, all NASDOX parameters were relative to bioavailability and metabolic conversion as denoted by F*.
For PYR, one-, two-, and three-compartment models (ADVAN 2, 4, and 12) with zero-, first-, and mixed-order absorption with or without lag time were tested. For the SDOX-NASDOX data set, SDOX was modeled alone initially with one-, two-, and three-compartment models (ADVAN 2, 4, and 12), including zero-, first-, and mixed-order absorption with or without lag time. After an adequate base structure was obtained for SDOX, additional compartments for NASDOX were added. Once the structure of the models was established, interindividual variability (IIV) and correlations between IIV terms were estimated, where supported by the data.
Finally, relationships between model parameters and covariates was examined. The covariates included pregnancy, coadministration of AZI (but not CQ given the lack of an interaction with SP [49] ), gestational age, maternal age, slide positive malaria, and hemoglobin were identified through inspection of scatterplots and boxplots of eta versus covariate and subsequently evaluated within NONMEM (71) . The effect size (%) of categorical data (pregnancy, AZI use, and slide positivity) was assessed, while both linear and power relationships were evaluated for continuous covariates (gestational age, maternal age, and hemoglobin). For effect size, the individual parameter value was calculated as follows:
population average ϫ ͑1 ϩ effect parameter ϫ covariate value͒ (1)
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population average ϫ ͩ1 ϩ effect parameter ϫ individual covariate value median covariate value ͪ (2) For power relationships, the individual parameter value was calculated as follows:
population average ϫ ͩ individual covariate value median covariate value ͪ effect parameter (3) The potential effect of AZI coadministration on relative bioavailability (F) was also assessed. A stepwise forward inclusion and backward elimination method was used with a significance of P Ͻ 0.05 required for inclusion of a covariate relationship and P Ͻ 0.01 to retain a covariate relationship.
Model evaluation. Initially, plots of observed versus individual and population predicted values, and time versus CWRES, were assessed. A bootstrap procedure using Perl speaks NONMEM (PSN) with 1,000 samples was performed, and the parameters derived from this analysis are summarized as median and 2.5th and 97.5th percentiles (95% empirical CI) to facilitate evaluation of final model parameter estimates. In addition, prediction corrected visual predictive checks (pcVPCs) and numerical predictive checks (NPCs) were determined with 1,000 data sets simulated from the final models. These were stratified according to pregnancy status and coadministration of AZI. The observed 10th, 50th, and 90th percentiles were plotted with their respective simulated 95% CIs to assess the predictive performance of the model. For NASDOX the fraction of data below the LOQ (BLQ) observed with the simulated 95% CI was also plotted for each time point.
Simulations. Based on the final models for PYR and SDOX, simulations for nonpregnant and pregnant women with or without coadministration of AZI were performed within NONMEM with 1,000 simulated individuals in each group. The nonpregnant no AZI group was used as a reference group for comparisons. A number of dose regimens were simulated, specifically, as follows: regimen A, conventional dosing (1 ϫ 1,500/75 mg of SP); regimen B, double conventional dose (1 ϫ 3,000/150 mg of SP); regimen C, two conventional doses (2 ϫ 1,500/75 mg of SP, 24 h apart); and regimen D, three conventional doses (3 ϫ 1,500/75 mg of SP, each 24 h apart). Since there are no published data suggesting that either drug exhibits complex pharmacokinetic properties, it was assumed that there were no time-or dose-dependent effects. The medians with 95% prediction intervals were obtained for clearance terms for PYR, SDOX, and NASDOX, as well as area under the curve (AUC), the maximum concentration (C max ), the time to maximum concentration (T max ), and the day 7 and 28 concentrations.
Statistical analysis. A Student t test or the Wilcoxon rank sum test for nonnormally distributed data were used for between-group comparisons. Categorical data were compared using either the Pearson chi-squared test or the Fisher exact test as appropriate. A two-tailed level of significance of P Ͻ 0.05 was used throughout.
